Navigation Links
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
Date:6/2/2013

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.

Chicago, IllinoisGBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months and few patients live beyond five years. GBM is characterized by angiogenesisthe formation of new blood vessels that support tumor growth stimulated by the GBM-produced vascular endothelial growth factor A (VEGF-A). Bevacizumab is a monoclonal antibody that targets VEGF-A production to block the growth of tumor-derived blood vessels. "Clinical trials evaluating the addition of bevacizumab to standard treatment for recurrent glioblastoma demonstrated clinical benefit and led to the drug's FDA approval for this indication," says Mark Gilbert, MD, RTOG 0825 Principal Investigator and professor of neuro-oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. "Additionally, compelling preclinical data suggest that anti-angiogenic targeted therapies may normalize the tumor's rapidly forming and underdeveloped blood vessels, resulting in improved oxygen and chemotherapy delivery to the tumor and potentially enhancing radiotherapy and chemotherapy treatment," explains Gilbert. The RTOG 0825 study tested this hypothesis.

Six hundred and thirty-seven adult study participants were enrolled in the multicenter trial and randomized into one of two study arms, with treating physicians blinded to treatment assignment. All participants were treated with standard radiotherapy (RT) (60 Gy) and daily temozolomide. Bevacizumab (experimental arm) or a plac
'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
2. Warmer soils release additional CO2 into atmosphere; Effect stabilizes over longer term
3. Additional research must be done to ensure safety of pit latrines, new study says
4. Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals
5. New data suggests HIV superinfection rate comparable to initial HIV infection
6. NLST: CT detects twice as many lung cancers as X-ray at initial screening exam
7. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
8. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
9. Genetic research develops tools for studying diseases, improving regenerative treatment
10. Step forward in research into new treatments for brain edema
11. Marshall University study may lead to new treatments for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... piece of the puzzle behind nature,s ability to ... help advance the development of artificial photosynthesis for ... by an international collaboration of scientists led by ... Lab) and the SLAC National Accelerator Laboratory. ... (LCLS), the world,s most powerful x-ray laser, the ...
(Date:7/9/2014)... of increasing concern about the prevalence of antibiotic-resistant ... promising new pathway to disabling disease: blocking bacteria,s ... scientists showed how bacterial siderophore, a small molecule, ... fan bacterial growth as well as how ... infection process. Their findings appear in a recent ...
(Date:7/9/2014)... penguins shows that the population is 3.79 million ... estimated. Adlie penguins have long been considered a ... effects of climate change and fishing in the ... researchers from Stony Brook University and University of ... regular monitoring of Adlie penguins across their entire ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... researchers from Princeton University and the Drexel University College ... malaria breaks down an important amino acid in its ... By depleting this substance called arginine, the parasite may ... disease. The scientists believe that shedding light on ...
... and University of Malaya (UM) today announced the establishment ... This is the first Centre of its kind in ... communities in terms of their diet and disease, conducting ... environment and health, providing assistance for the national cancer ...
... of the oil in the ocean bubbles up naturally from ... was of no value. Likewise, NASA satellites collect thousands of ... of it gets passed over because no one thinks there ... black gold bubbling up from an otherwise undistinguished mass of ...
Cached Biology News:Malaria parasite zeroes in on molecule to enhance its survival, team finds 2Malaria parasite zeroes in on molecule to enhance its survival, team finds 3Queen's University Belfast improves Malaysian public health 2Scientists find black gold amidst overlooked data 2Scientists find black gold amidst overlooked data 3
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2011 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the ... issue of the journal Science regarding the ... omecamtiv mecarbil, and the potential therapeutic role that this ... failure. This publication reveals, for the first time ...
... and ST. GALLEN, Switzerland, March 17, 2011 Genomic ... results from nine studies utilizing the Onco type ... 12th Annual St. Gallen International Breast Cancer Conference in ... data that demonstrated the knowledge of a patient,s Recurrence ...
... Inc., a consulting firm that specializes in maximizing sales ... as Executive Account Director. Weimer has gained recognition and ... develop and inspire his teams to attain personal excellence ... organization,s goals. Delta Point CEO and founder ...
Cached Biology Technology:Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 2Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 3Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 2Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 3Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 4Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 5Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 6Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 7Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 8Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2
... (M-MLV RT) is an RNA-dependent DNA polymerase that ... messenger RNA templates (>5kb). The enzyme is a ... consists of a single subunit with a molecular ... M-MLV RT is weaker than the commonly used ...
... the determination of digitonin and digoxin. Physical form: ... 4 and 0.06% NaCl Preparation Note: Sodium ... Biophys. Res. Commun., 19, 755 (1965). Unit ... inorganic phosphorus from ATP per min at pH ...
kismet (dK-20)...
... design allows "4 gels in one tank",electrophoresis. ... to run 200,samples or more in one ... four,horizontal gels. To ensure even migration, the ... of gels being run. Ideal for,high throughput ...
Biology Products: